Search
-
New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age
Media
New data published in The Lancet from a Phase III clinical trial with Fluarix Tetra which prevented influenza in children 6 to 35 months
https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/
First published: 06 March 2018
-
Results announcement for the fourth quarter 2016
Media
View full Q4 2016 Results (PDF)
https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/
First published: 08 February 2017
-
GSK announces first approval of Shingrix in Canada
Media
The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over
https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-approval-of-shingrix-in-canada/
First published: 13 October 2017
-
China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma
Media
The China National Medical Products Administration (NMPA) has accepted for review a new drug application for Nucala (mepolizumab)
https://www.gsk.com/en-gb/media/press-releases/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma/
First published: 14 March 2023
-
Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over
Media
Approval expands the number of people who can be protected against shingles.
https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over/
First published: 26 June 2023
-
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
Media
Organisations from South Africa, Zambia, Kenya and Uganda and Save the Children for innovations proven to help reduce deaths in under-fives
https://www.gsk.com/en-gb/media/press-releases/four-initiatives-from-across-africa-win-share-of-global-us-1-million-healthcare-innovation-award/
First published: 29 January 2015
-
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
Media
Healthcare Innovation Award is a major initiative within five-year partnership to help save one million children’s lives
https://www.gsk.com/en-gb/media/press-releases/four-inspiring-innovations-which-help-reduce-child-deaths-in-developing-countries-share-1-million-prize-from-gsk-and-save-the-children/
First published: 23 February 2016
-
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Media
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/
First published: 21 May 2018
-
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
Media
GSK today announced new 48-week data from the MOMENTUM phase III trial...
https://www.gsk.com/en-gb/media/press-releases/new-data-at-ash-underscore-the-potential-for-durable-clinically-important-responses-with-momelotinib-for-myelofibrosis-patients/
First published: 11 December 2022
-
Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan
Media
GSK and THRX announced intention to file sJNDA for Relvar® Ellipta® for the treatment of COPD with the Japanese authority during the Q12016.
https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvar-ellipta-for-copd-in-japan/
First published: 24 September 2015